[1]. IPRP. Expectations for Biodistribution(BD) Assessments for Gene Therapy(GT) Products [J]. http://admin.iprp.global/sites/default/files/2018-09/IPRP_GTWG_Reflection Paper_BD_Final_2018_0713.pdf

[2]. FDA. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products[EB/ OL]. 2013. https: //www. fda. gov/regulatory-information/ search-fda-guidance documents/preclinical-assessment- in-vestigational-cellular-and-gene-therapy-products.

[3]. ICH M3(R2). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals [EB/OL].June 2009. https: //www.ich. org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2_Guideline. pdf.

[4].FDA/CBER. Draft Guidance for Industry: Long Term Follow-Up After Administration of Human Gene Therapy Products[EB/OL]. July 2018. https: //www. fda. gov/me-dia/113768/download.

[5]. The Definition of Gene Therapy Has Changed. https://doi.org/10.1038/d41586-021-02736-8. Published online 26 October 2021.

[6]. Distribution of chimeric antigen receptor modified T cells against CD19 in B-cell malignancies. https://doi.org/10.1186/s12885-021-07934-1.

[7]. EMA/CAT. Guideline on the quality，non-clinical and clinical aspects of gene therapy medicinal products[EB/OL]. March 2018. https：//www. ema. europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clini-cal-aspects-gene-therapy-medicinal-products_en. pdf.

[8]. Silva Lima B，Videira MA. Toxicology and biodistribution: the clinical value of animal biodistribution studies [J]. Mol Ther Methods Clin Dev, 2018, 8: 183-197.

[9]. ICH. General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors. 2006.

[10]. Biodistribution studies for cell therapy products: Current status and issues. https://doi.org/10.1016/j.reth.2021.06.005.

[11]. EMA. Guideline on the Non-clinical Studies Required Before First Clinical Use of Gene Therapy Medicinal Products. 2008.

[12]. Richard O. Snyder and Philippe Moullier, Adeno-Associated Virus: Methods and Protocols, Methods in Molecular Biology, vol. 807, DOI 10.1007/978-1-61779-370-7_15.

[13]. David R Compton, Steven J DeMarco , and Padmaja Yalamanchili. AAV2-hAADC (Eladocagene Exuparvovec) Biodistribution and Expression: Superiority of  Intraputaminal versus Intracerebroventricular and Intrathecal (Lumbar) Routes of Administration. nternational Journal of Toxicology 2023, Vol. 42(2) 135–145